China Pharma Holdings (CPHI) Other Non-Current Liabilities (2010 - 2023)

China Pharma Holdings (CPHI) has reported Other Non-Current Liabilities for 10 consecutive years, with $2.2 million the latest figure, recorded in Q1 2023.

• For the quarter ending Q1 2023, Other Non-Current Liabilities changed N/A year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2023 stood at $2.2 million (changed N/A YoY), and the FY2022 full-year result was $2.4 million, up 26.85% from the prior year.
• Other Non-Current Liabilities fell to $2.2 million in Q1 2023 per CPHI's latest filing, from $2.4 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $3.1 million in Q2 2021 and bottomed at $1.7 million in Q3 2021.
• Historically, Other Non-Current Liabilities has averaged $2.3 million across 5 years, with a median of $2.4 million in 2022.
• The sharpest annual moves came in 2021 and 2022: Other Non-Current Liabilities tumbled 31.44% in 2021, then advanced 26.85% in 2022.
• Over 5 years, Other Non-Current Liabilities stood at $2.4 million in 2019, then gained by 14.44% to $2.7 million in 2020, then sank by 31.44% to $1.9 million in 2021, then grew by 26.85% to $2.4 million in 2022, then retreated by 9.15% to $2.2 million in 2023.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $2.2 million, $2.4 million, and $1.9 million for Q1 2023, Q4 2022, and Q4 2021 respectively.